Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:7/6/2009

SAN DIEGO, July 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its 5% Series B convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $1.36 million. Twenty-five percent, or approximately $340,250, of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described below.

The preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investor at a price of $0.1432 per share and will accrue a 5% dividend until July 6, 2014. If the convertible preferred stock is converted at any time prior to July 6, 2014, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through July 6, 2014, or $250 per $1,000 principal amount of convertible preferred shares converted, less any dividend payments made with respect to such converted convertible preferred shares.

ADVENTRX plans to use the net proceeds from the offering to fund activities related to seeking FDA approval to market ANX-530 (vinorelbine emulsion) in the United States, including manufacturing-related activities, and for general corporate purposes, including general and administrative expenses.

The shares were sold by ADVENTRX pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). A prospectus supplement relating to the offering was filed with the SEC on June 30, 2009. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: '/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
2. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
3. ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
4. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
5. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
6. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
7. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
8. ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 30, 2014 VogueQueen.com, a ... steps with the newest trends in garment fashion by ... the company is selling an all-inclusive array of ... When shopping online, a lot of customers take price ... promotions frequently. That makes the purchase more affordable for ...
(Date:7/29/2014)... a form of acupuncture where a small electric ... produces significant improvements in fatigue, anxiety and ... early stage breast cancer patients experiencing joint pain ... to treat breast cancer. The results of a ... researchers at the Perelman School of Medicine at ...
(Date:7/29/2014)... Diabetes is a common condition diagnosed in millions of people. ... while the production of insulin is decreased. , Insulin ... needed by the body to regulate blood sugar levels. Diabetes ... as there are numerous complications that can be developed by ... read a complex review of Matt Traverso's new book go ...
(Date:7/29/2014)... 2014 DailyGossip.org reveals in its Stop ... a new method of naturally overcoming sciatica, in less ... new method ensure sufferers that the cure is simple ... , The new method is described as very fast, ... with an 8 minutes per day treatment plan. ...
(Date:7/29/2014)... WA, Australia (PRWEB) July 30, 2014 ... regulation of medical devices have determined Nurse Call ... and international legislation, this requires all Nurse Call ... This regulatory practice improves patient safety, reduces clinical ... and private hospital based Corporate Risk and Clinical ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4
... like a smart bomb for cancer treatment is to be ... penetrating into the tumor, seal the opening and then ... bimb’.// This will leave the healthy cells unharmed. ... lung cancer have the potential of being a revolutionary form ...
... study that appears in the current edition of The ... be at high risk from becoming infertile.//, ,Female ... countries. The World Health Organization estimates that more than ... FGM, and that about 2million procedures are done every ...
... disease is believed to be caused by Streptococcus suis and ... province of China. The infected persons were mostly farmers and ... contaminated pork products. According to investigations in China, the infected ... different farms, which were then spread across 70 areas in ...
... Lviv Regional Oncology center//, Ukraine has developed a new ... breast and ovarian cancer. ,However, they did not ... find a single reliable early protein, or 'marker', for ... successful," says LICR's Serhiy Souchelnytskyi, senior author of the ...
... people are not aware of their learning experience//. The research ... ,Researchers from University of California, San Diego School of ... undertaken the study to find out if like animals humans ... not aware of doing so. ,Habit learning occurs when ...
... used for thousands of years to prevent or treat nausea, ... people with cancer avoid the nausea induced by chemotherapy. ... them avoid this unpleasant side effect. But for most people, ... of nausea may hit. ,Researchers now say they ...
Cached Medicine News:Health News:An Anti-cancer Smart Bomb delivered using a Nanocell 2Health News:An Anti-cancer Smart Bomb delivered using a Nanocell 3Health News:Girls Who Undergo Genital Mutilation Can Become Infertile 2Health News:Molecular markers for early diagnosis of breast and ovarian cancer 2Health News:Habit Memory May Enhance Learning In People 2
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014  Alexza ... that it is participating in two healthcare conferences during ... Conference and the Morgan Stanley Global Healthcare 2014 Conference. ... Morgan Stanley Conference.  The details on each event are ... Conference, Monday, August 11, 2014 in Boston ...
(Date:7/29/2014)... 2014  Covance Inc. (NYSE: CVD ) ... 30, 2014.  Net revenue was $639 million, representing 8.0% ... GAAP basis, the company reported earnings of $0.29 per ... pro forma earnings per diluted share of $0.95, up ... results exclude asset impairment charges totaling $52.6 million, or ...
(Date:7/29/2014)... , July 29, 2014 New technology ... which could allow physicians to see and assess brain ... promise, according to study authors who released their findings ... th Annual Meeting in Colorado Springs, ... advance the field of neurointervention, a specialty that facilitates ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 ... the commercial prospects for lyophilisation technology? ...
...  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... the 2011 Deutsche Bank BioFEST scheduled for Monday, December ... Eastern Time.  The session may be accessed through the ... Relations page.  An archived version of the presentation will ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 13Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: